Kenji Ueki

Kenji Ueki

Auto-generated profile, based on publicly available information

Kenji Ueki

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2016 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
SYShunsuke Yamada
Shunsuke Yamada
Kazuhiko TsuruyaKazuhiko Tsuruya
Kazuhiko Tsuruya
HYHisako Yoshida
Hisako Yoshida
MTMasanori Tokumoto
Masanori Tokumoto
KUKenji Ueki
Kenji Ueki
TKTakanari Kitazono
Takanari Kitazono

2 June 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KNKaneyasu Nakagawa
Kaneyasu Nakagawa
ATAkihiro Tsuchimoto
Akihiro Tsuchimoto
KUKenji Ueki
Kenji Ueki
YMYuta Matsukuma
Yuta Matsukuma
YOYasuhiro Okabe
Yasuhiro Okabe
JIJapan Academic Consortium of Kidney Transplantation Investigators
Japan Academic Consortium of Kidney Transplantation Investigators
Diagnostic criteria for chronic active T‐cell mediated rejection (CA‐TCMR) were revised in the Banff 2017 consensus, but it is unknown whether the new criteria predict graft prognosis of kidney transplantation. We enrolled 406 kidney allograft recipients who underwent a 1‐year protocol biopsy (PB) and investigated the diagnostic significance of Banff 2017. Interobserver reproducibility of the three diagnosticians showed a substantial agreement rate of 0.68 in Fleiss’s kappa coefficient. Thirty‐three patients (8%) were classified as CA‐TCMR according to Banff 2017, and 6 were previously diagnosed as normal, 12 as acute TCMR, 10 with borderline changes, and 5 as CA‐TCMR according to Banff 2015 criteria. Determinant factors of CA‐TCMR were cyclosporine use (vs. tacrolimus), previous acute rejection, and BK polyomavirus‐associated nephropathy. In survival analysis, the new diagnosis of CA‐TCMR predicted a composite graft endpoint defined as doubling serum creatinine or death‐censored graft loss (log‐rank test, P <0.001). In multivariate analysis, CA‐TCMR was associated with the second highest risk of the composite endpoint (hazard ratio: 5.42; 95% confidence interval, 2.02–14.61; P <0.001, vs. normal) behind antibody‐mediated rejection. In conclusion, diagnosis of CA‐TCMR in Banff 2017 may facilitate detecting an unfavorable prognosis of kidney allograft recipients who undergo a 1‐year PB.

1 July 2004 in Environmental Monitoring and Assessment
Verified
Journal Article
Closed access
PDF file
MTManisha Thakur
Manisha Thakur
MDManas Kanti Deb
Manas Kanti Deb
SIS. Imai
S. Imai
YSY. Suzuki
Y. Suzuki
KUK. Ueki
K. Ueki
AHA. Hasegawa
A. Hasegawa

1 January 1997 in TRANSACTIONS OF THE JAPAN SOCIETY OF MECHANICAL ENGINEERS Series C
Verified
Journal Article
Open access
HIHiroaki Ishida
Hiroaki Ishida
MMMasaki Matsuo
Masaki Matsuo
KTKazuhiko Tezuka
Kazuhiko Tezuka
KUKenji Ueki
Kenji Ueki

1 January 2015 in Internal Medicine
Verified
Journal Article
Closed access
KUKenji Ueki
Kenji Ueki
SYShunsuke Yamada
Shunsuke Yamada
ATAkihiro Tsuchimoto
Akihiro Tsuchimoto
MTMasanori Tokumoto
Masanori Tokumoto
TKTakashi Kumano
Takashi Kumano
KTKazuhiko Tsuruya
Kazuhiko Tsuruya
We herein present the case of a patient with myeloma and chronic kidney disease (CKD) who developed rapidly progressive vascular and soft tissue calcification during the course of treatment for severe hypocalcemia induced by the administration of denosumab for myeloma and hypercalcemia. Because a large amount of supplementation with active vitamin D and calcium was required to correct the severe hypocalcemia, rapidly progressive vascular calcification developed. Seeing that patients with CKD are prone to developing severe and prolonged hypocalcemia after denosumab treatment, physicians should closely monitor the patients' serum calcium levels and manage their hypocalcemia appropriately so as to avoid the development of significant ectopic calcification.

20 October 2015 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
SYShunsuke Yamada
Shunsuke Yamada
KUKenji Ueki
Kenji Ueki
MTMasanori Tokumoto
Masanori Tokumoto
TSTakaichi Suehiro
Takaichi Suehiro
HKHiroshi Kimura
Hiroshi Kimura
Kazuhiko TsuruyaKazuhiko Tsuruya
Kazuhiko Tsuruya